Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- Ileal Bile Acid Transporter Inhibitor FDA class
- Tested for
- Pruritus
- Main trialPhase 3
- “This study evaluates the long-term safety and tolerability of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358). Participants will continue receiving linerixibat while researchers monitor adverse events and other safety measures to better understand the long-term safety of treatment and provide continued access to therapy.”In the company’s words, NCT07860710 on ClinicalTrials.gov
- Other names
- GSK2330672
Other drugs for Pruritus
- SD-101TriSalus Life Sciences, Inc. · Phase 3
- DupilumabRegeneron · Sanofi · Phase 3
- FexofenadineSanofi · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 3
- RitlecitinibPfizer · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
Coming up1
- 23 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT04167358
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 23 Oct 2028 | J-LINX: Japan LINerixibat eXtension Study | |
| Phase 3Completed | 30 Sep 2026 | Linerixibat Long-term Safety, and Tolerability Study | |
| Phase 2Completed | 15 Apr 2020 | Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026